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Abstract  27 
Alpha-synuclein is known to bind to small unilamellar vesicles (SUVs) via its N-terminus 28 
which forms an amphipathic alpha-helix upon membrane interaction. Here we show that 29 
calcium binds to the C-terminus of alpha-synuclein, therewith increasing its lipid binding 30 
capacity. Using CEST-NMR we reveal that alpha-synuclein interacts with isolated synaptic 31 
vesicles with two regions, the N-terminus, already known from studies on SUVs, and 32 
additionally via its C-terminus, which is regulated by the binding of calcium. Indeed, dSTORM 33 
on synaptosomes shows that calcium mediates the localization of alpha-synuclein at the 34 
presynaptic terminal, and an imbalance in calcium or alpha-synuclein can cause synaptic 35 
vesicle clustering, as seen ex vivo and in vitro. This study provides a new view on the binding 36 
of alpha-synuclein to synaptic vesicles, which might also affect our understanding of 37 
synucleinopathies.  38 
 39 
 40 
 41 
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INTRODUCTION 51 
Alpha-synuclein is a 140-residue protein, which constitutes three major protein regions, the 52 
N-terminus (aa 1-60), the non-amyloid-β component (NAC) region (aa 61-95), designated as 53 
the aggregation-prone region, and the C-terminus (aa 96-140). Alpha-synuclein is localized at 54 
the presynaptic terminals 1, and, while structurally disordered in solution 2,3, it also exists in a 55 
partially structured, membrane bound form. Indeed, alpha-synuclein can bind a variety of 56 
synthetic vesicles but displays a preference to bind to small, highly curved synthetic vesicles 57 
via its N-terminus 4–10. NMR studies of alpha-synuclein binding to synaptic-like synthetic 58 
vesicles have shown that this interaction is primarily triggered by the N-terminal residues, 59 
but interactions propagate up to residue 98, with the central region of the protein (residues 60 
65-97) having a key role in modulating the binding affinity to the membrane 11 and in 61 
promoting the clustering of synaptic vesicles 12.  62 
 63 
Moreover, although it has been shown that the N-terminus of alpha-synuclein strongly 64 
interacts with lipid vesicles, it is important to note that so far all research on alpha-synuclein-65 
lipid interactions has been carried out on synthetic lipid vesicles. It thus has yet to be shown 66 
how alpha-synuclein interacts with physiological synaptic vesicles which are clearly distinct 67 
from just lipid vesicles 13.  68 
 69 
We hypothesised that calcium plays a role in the normal physiological function of alpha-70 
synuclein since alpha-synuclein is primarily localised at the presynaptic terminals where high 71 
calcium fluctuations occur, ranging up to hundreds of µM 14,15, and since calcium has been 72 
previously shown to bind to alpha-synuclein at its C-terminus 16. In addition, it is not clear 73 
what the calcium affinity to alpha-synuclein is, whether the C-terminus is equally amenable 74 
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to cations in the presence of synaptic vesicles, and how exposure to calcium would interfere 75 
with the synaptic vesicle binding capacity of alpha-synuclein. To answer these questions, we 76 
investigated firstly the calcium-binding properties of alpha-synuclein by NMR and Mass 77 
spectrometry (MS). We then explored whether and how neutralisation of negative charges 78 
on the C-terminus impacts on the interaction of alpha-synuclein with lipids and synaptic 79 
vesicles. And finally, we tested whether the interaction of alpha-synuclein with synaptic 80 
vesicles impacts on synaptic vesicle homeostasis and on alpha-synuclein aggregation and 81 
toxicity related to Parkinson’s disease (PD). 82 
 83 
We show here that calcium interacts with the negatively charged C-terminus of alpha-84 
synuclein, having a KD in the range of 21 µM. Using synaptic vesicles isolated from rat brain, 85 
we performed chemical exchange saturation transfer (CEST) experiments in solution-state 86 
NMR, and show that the C-terminus of alpha-synuclein has an increased tendency to interact 87 
with synaptic vesicles upon calcium binding. In the presence of calcium, alpha-synuclein 88 
exhibited specific clustering at the presynaptic terminal, which could be reversed by the 89 
addition of a calcium chelator. In contrast, VAMP-2, a synaptic vesicle marker, was not 90 
affected by these calcium changes. These findings suggest that the normal physiological role 91 
of alpha-synuclein is to act as a calcium-dependent modulator of vesicle homeostasis at the 92 
presynaptic terminal. Using ventral mesencephalic neurons, we further show that treatment 93 
with dopamine, a neurotransmitter relevant in PD pathology, promoted the clustering of 94 
alpha-synuclein positive vesicles. The latter was prevented by treatment with isradipine, a 95 
voltage-gated calcium channel inhibitor. Furthermore, lowering either the levels of alpha-96 
synuclein or calcium prevented dopamine toxicity, indicating that both alpha-synuclein and 97 
calcium levels need to be finely balanced. This study provides a new view on the binding of 98 
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alpha-synuclein to synaptic vesicles, which might also affect our understanding of 99 
synucleinopathies. 100 
 101 
Results  102 
Calcium increases the lipid binding of α-synuclein 103 
We recorded 1H-15N heteronuclear single quantum correlation (HSQC) spectra of alpha-104 
synuclein in solution NMR as a function of calcium concentration to determine the 105 
thermodynamics and structural nature of the calcium binding mechanism. An analysis of the 106 
spectra identified the C-terminus as the primary segment hosting chemical shift 107 
perturbations due to calcium binding. In addition, we found peak broadening for some 108 
residues in the NAC-region. Residues whose chemical shifts of the backbone amide N-H were 109 
mostly affected are aa 104, 107, 112, 119, 123, 124, 126, 127, 129, 130, 135, 136, 137 (Fig. 110 
1a and Supplementary Fig. 1). In order to obtain information on the thermodynamics of the 111 
calcium affinity to alpha-synuclein, and since the number of calcium cations that are bound 112 
to alpha-synuclein was not known, we performed a global analysis by fitting the chemical 113 
shift perturbation using a multiple ligand model 17, which allows to estimate the binding 114 
constant when the exact number of ligands is not known. Similar models have also been 115 
used before to analyse multivalent interactions of other amyloidogenic proteins 18. By 116 
performing best fit analysis we obtained a KD of calcium affinity of 21 µM with the number of 117 
ligand cations, L, being 7.8 (Fig. 1b).  118 
In order to provide further support on the number of ligand cations being bound to alpha-119 
synuclein we performed electrospray ionisation mass spectrometry (MS) and found that at 120 
least six cations are bound to alpha-synuclein (Fig. 1c and Supplementary Table 1). We thus 121 
confirmed by two independent measurements that around 6-8 calcium ions can be bound to 122 
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alpha-synuclein providing further support of our determined KD. A dissociation constant of 123 
21 µM lies well within the range of physiological pre-synaptic calcium fluctuations, reaching 124 
up to hundreds of µM in healthy neurons upon neuronal stimulation 14,15.  125 
 126 
We then hypothesised that a neutralisation of negative charges on residues at the C-127 
terminus via dynamic binding of positively charged calcium ions facilitates the interaction of 128 
alpha-synuclein with phospholipid membranes. To test this hypothesis, we incubated lipid 129 
Folch extracts from bovine brain with alpha-synuclein in the presence of calcium and other 130 
ions, including potassium, sodium and magnesium and measured the interaction of alpha-131 
synuclein with lipids via lipid pull-down. In the presence of calcium, the amount of alpha-132 
synuclein that precipitated with the lipids increased about 5-fold. Magnesium and a high 133 
concentration of sodium ions also increased the amount of alpha-synuclein pulled down, but 134 
not to the same extent as calcium (Fig. 1d and Supplementary Fig 2). A phase partitioning 135 
assay further established that the hydrophobicity of alpha-synuclein increases upon calcium 136 
addition, which is manifested by a higher abundance of the protein in the lipophilic 137 
detergent phase (Supplementary Fig. 3). 138 
 139 
The C-terminus of α-synuclein binds to synaptic vesicles  140 
Having seen that calcium influences the binding of alpha-synuclein to lipids, we investigated 141 
the interaction of alpha-synuclein with synaptic vesicles isolated from rat brain and its 142 
dependence on calcium. Using measurements of chemical exchange saturation transfer 143 
(CEST) in solution NMR 11,12 we probed the binding affinity along the protein sequence. This 144 
analysis revealed that in the absence of calcium the interaction with synaptic vesicles was 145 
strongest via the N-terminus. In the presence of calcium, however, the interaction of the C-146 
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terminus and also for some residues of the NAC-region was increased (Fig. 2a), providing 147 
further insight into how calcium can modify the C-terminus of alpha-synuclein and thereby 148 
induce a stronger interaction with synaptic vesicles. To determine whether a calcium-149 
dependent lipid interaction is transient, and therefore dynamically regulated, we again 150 
performed lipid pull down experiments. We show that, consistent with the fast exchange 151 
regime observed in solution NMR, the calcium-dependent interaction of alpha-synuclein is 152 
dynamic, as addition of the calcium chelator EGTA reverses calcium-mediated alpha-153 
synuclein lipid binding (Fig. 2b).  154 
 155 
α-synuclein is modulated by calcium at presynaptic terminals 156 
Synaptosomes, pinched off synapses that reseal as spherical droplets, were isolated from rat 157 
brain and used to study the synaptic localization of alpha-synuclein in the presence or 158 
absence of calcium. Using direct stochastic optical reconstruction microscopy (dSTORM), 159 
permitting sub-diffraction resolution imaging, we found that under normal physiological 160 
conditions (low intracellular and high extracellular calcium concentrations) alpha-synuclein 161 
was significantly polarized.  This could be interpreted as if alpha-synuclein does not bind to 162 
synaptic vesicles, however, our vitro data as well as data from previous reports 5–10 show a 163 
strong binding of alpha-synuclein to synaptic vesicles. The polarization could therefore be 164 
interpreted as a binding of alpha-synuclein to only a subset of synaptic vesicles (similar to 165 
what has been indicated in Lee et al.19). When we depleted calcium in the extracellular 166 
buffer by the addition of the calcium chelator EGTA and omitting calcium, alpha-synuclein 167 
displayed a dispersed distribution throughout the synaptosome (Fig. 2c and Supplementary 168 
Fig. 4).  169 
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The cluster sizes of the synaptosomal alpha-synuclein and synaptic vesicle associated protein 170 
2 (VAMP2), were determined by cluster analysis and revealed that alpha-synuclein was 171 
significantly more dispersed upon calcium starvation with EGTA, while calcium starvation 172 
had no effect on the localization of VAMP2 (Fig. 2d). In order to address whether an increase 173 
in intracellular calcium leads to a further clustering of alpha synuclein we stimulated the 174 
synaptosomes with an extracellular solution at 70 mM KCl, which leads to membrane 175 
depolarization and calcium influx via voltage-gated calcium channels. Our results show that 176 
upon stimulation there is no further change in the distribution of alpha-synuclein throughout 177 
the synaptosomes (Supplementary Fig. 5), suggesting that normal physiological calcium 178 
concentrations are sufficient to induce alpha-synuclein clustering. The specificity of the 179 
alpha-synuclein staining protocol was validated using synaptosomes derived from alpha-180 
synuclein knock-out mice (Supplementary Fig. 6). Furthermore, using synaptosomes from 181 
wild type human alpha-synuclein overexpressing mice we see that alpha-synuclein loses its 182 
ability to be specifically polarized under normal physiological conditions (Supplementary Fig. 183 
7).  184 
 185 
α-synuclein and calcium regulate synaptic vesicle interaction 186 
Using NMR and synthetic lipids we have shown recently that alpha-synuclein is capable of 187 
tethering vesicles and two protein regions were identified as participants in a double anchor 188 
mechanism12. In order to quantify the dependencies of synaptic vesicle clustering on calcium 189 
and alpha-synuclein, synaptic vesicles purified from rat brains were incubated with either 1 190 
mM EGTA omitting calcium or 200 µM calcium and subsequently imaged using stimulated 191 
emission depletion (STED) microscopy. For samples incubated with EGTA 88% of synaptic 192 
vesicles were distributed as single vesicles, while 12% showed clustering with one or more 193 
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vesicles. However, in the presence of calcium the amount of single vesicles decreased to 194 
84% and the number of multiple vesicles clustering together increased to 16%. This indicates 195 
that, even for synaptic vesicles isolated from wild-type rat brain with endogenous levels of 196 
alpha-synuclein present, calcium is a modulating factor of the cohesion between synaptic 197 
vesicles. Next, we incubated synaptic vesicles with 200 µM of calcium and 50 µM of 198 
recombinant alpha-synuclein, which, in combination with the endogenous alpha-synuclein, 199 
leads to doubling of the level of alpha-synuclein present on synaptic vesicles 13. Again, a 200 
significant clustering of synaptic vesicles was observed with 81% distributed as single 201 
synaptic vesicles and 19% as multiple vesicle clusters.  Incubating synaptic vesicles with 50 202 
µM of recombinant alpha-synuclein and 1 mM EGTA in combination, did however not 203 
reverse synaptic vesicle clustering, indicating that the presence of an increased alpha-204 
synuclein level on its own can already induce synaptic vesicle clustering (Fig. 3a). A clustering 205 
of synaptic vesicles upon incubation with 50 µM of alpha-synuclein was also observed via 206 
transmission electron microscopy (Fig. 3b) and via combined confocal/STED imaging, the 207 
latter verifying that synaptic vesicles colocalized with alpha-synuclein (Fig. 3c).  208 
 209 
Next, we studied the behaviour of endogenous alpha-synuclein in ventral midbrain (VM) 210 
neurons incubated with 100 µM dopamine. This system has previously been shown to 211 
induce the formation of alpha-synuclein oligomers and to exhibit dopaminergic neuron-212 
specific toxicity 20–23. VM neurons treated with dopamine for 72 h were stained against 213 
endogenous alpha-synuclein and the synaptic vesicle protein synaptotagmin 1 and 214 
subsequently imaged by dSTORM. Upon incubation with dopamine, an increase in the area 215 
of alpha-synuclein-positive puncta was observed, together with an increased size of 216 
synaptotagmin 1 puncta and an increased colocalization of alpha-synuclein and 217 
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synaptotagmin 1 (Fig. 4a-c). We show that these dopamine-induced changes were reversed 218 
by treating the cells with isradipine, a CaV1.3 calcium channel antagonist previously reported 219 
to block dopaminergic neuron cell death in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 220 
(MPTP) and other neurotoxin-related Parkinson’s disease models 24. This demonstrates that 221 
in the presence of endogenous alpha-synuclein levels calcium is necessary to induce synaptic 222 
vesicle clustering, consistent with our observations from isolated synaptic vesicles. Since 223 
isradipine was seen to significantly reduce clustering of alpha-synuclein, we tested if also 224 
dopamine-induced cytotoxicity might be suppressed as a consequence of its action. Our data 225 
show that dopamine-induced toxicity can be abolished both by the administration of 226 
isradipine, or by knocking down of alpha-synuclein (Fig. 4d, Supplementary Fig. 8), indicating 227 
that high levels of calcium and/or alpha-synuclein are key elements of neuronal toxicity.  228 
 229 
Calcium and synaptic vesicles affect α-synuclein aggregation 230 
Taken together our data indicate that calcium mediates the interaction of alpha-synuclein 231 
and synaptic vesicles and that this has an effect in both physiological processes and under 232 
conditions generating cellular toxicity. However, since both, either increased levels of alpha-233 
synuclein or calcium can induce cell death, we investigated whether calcium and synaptic 234 
vesicles may influence the aggregation propensity of alpha-synuclein. To test this hypothesis, 235 
we performed Thioflavin T (ThT) fluorescence assays of alpha-synuclein aggregation, and 236 
analysed the effect of increased calcium in the presence and absence of synaptic vesicles 237 
(Fig. 5a). The lag time for each condition was calculated from the averaged aggregation 238 
curves by linear extension of the elongation phase. The nucleation rate (k1) and the 239 
elongation rate (k2) were fitted using the Finke-Watzky equation for a two-step aggregation 240 
mechanism 25. This analysis clearly revealed that calcium aggravates alpha-synuclein 241 
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aggregation, showing a lag time decrease from 79 hours for ‘EGTA only’ to 4 hours for 242 
‘calcium only’. Accordingly, the nucleation rate was increased 2-fold in the presence of 243 
calcium, and the elongation rate was increased 1.3-fold. Moreover, the amount of residual 244 
monomer left at the end of the aggregation assay was significantly lower when calcium was 245 
present, confirming the higher aggregation propensity of alpha-synuclein in the presence of 246 
calcium. In the presence synaptic vesicles and calcium, we observed the highest nucleation 247 
and elongation rate. In the absence of calcium, synaptic vesicles decreased the lag time from 248 
79 hours to 44 hours and increased the nucleation rate 2-fold compared to the ‘EGTA only’ 249 
group, which is in accordance with what has been reported for synthetic vesicles 17. 250 
However, the elongation rate was not increased (Table 1).  251 
Interestingly, alpha-synuclein fibrils formed at the end of the assay showed a different 252 
morphology when synaptic vesicles were present during the aggregation process. When 253 
alpha-synuclein was incubated in the presence of calcium and synaptic vesicles, alpha-254 
synuclein fibrils were shorter and showed aggravated bundling. In the presence of EGTA 255 
significantly less fibrils were found. The few fibrils that could be found in the EGTA group 256 
without synaptic vesicles were long and separated whereas the EGTA fibrils formed in the 257 
presence of synaptic vesicles appeared to have an intermediate phenotype as they were still 258 
bundled but longer than fibrils formed in the presence of synaptic vesicles and calcium (Fig. 259 
5b). In order to confirm the presence of synaptic vesicles during the aggregation process we 260 
show a TEM image of alpha-synuclein in the presence of synaptic vesicles at the beginning of 261 
the aggregation experiment (Supplementary Fig. 9), as after seven days the vesicles cannot 262 
be detected on the TEM anymore. 263 
 264 
Discussion 265 
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The C-terminus of alpha-synuclein is negatively charged such that electrostatic interaction 266 
can take place with cations 16. In the past, however, research on such interactions has 267 
predominantly been focused on metal ions as environmental factors inducing alpha-268 
synuclein aggregation 26–28. Here, we focus on the interaction of alpha-synuclein with 269 
physiological calcium, since at the presynaptic terminal, where alpha-synucleins primarily 270 
resides, large fluctuations in calcium levels are known to occur 14,15. We quantify and localise 271 
the interactions of calcium with alpha synuclein using 1H-15N HSQC NMR and observe 272 
significant chemical shift perturbations for a number of residues at the C-terminus of the 273 
protein. Furthermore, significant peak broadening takes place in the NAC-region of alpha-274 
synucein in the presence of calcium. This can be interpreted either as a conformational 275 
change in the NAC-region induced upon calcium binding at the C-terminus, or as an 276 
interaction between multiple NAC-regions when individual alpha-synuclein molecules cluster 277 
due to charge neutralisation. The affinity of calcium was found to be around 21 µM, which is 278 
lower than reported for other multivalent cations 27. While levels of calcium are in the tens 279 
of nM range under resting conditions 29, it’s concentration rises to several hundred µM 280 
within microdomains during depolarization of neurons as a result of a concomitant calcium 281 
influx via voltage-gated calcium channels 14,15. In this context, the observed KD of 21 µM 282 
highlights the physiological relevance of the interaction between alpha-synuclein and 283 
calcium. 284 
 285 
CEST-NMR experiments, analysing the interaction of alpha-synuclein with synaptic vesicles 286 
from rat brain, verified that in the presence of calcium the C-terminus has a higher affinity to 287 
bind to synaptic vesicles. In a previous study 12 we have shown that the modes of binding of 288 
the N-terminal and NAC-region of alpha-synuclein to small unilammelar vesicles (SUVs) of 289 
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DOPE:DOPS:DOPC (in 5:3:2 molar ratios) 11,12,30 are independent of each other. This degree 290 
of independence suggested that the two regions can bind the same vesicle but also multiple 291 
vesicles. We referred to this N-terminus and NAC-region binding of alpha-synuclein to SUVs 292 
as double anchor mechanism. We now have characterised the binding of alpha-synuclein to 293 
synaptic vesicles isolated from rat brain using CEST NMR, showing again that the strongest 294 
binding occurs at the N-terminus and revealing an intermediate level of synaptic vesicle 295 
interaction of the NAC-region and the C-terminus. Interestingly, upon addition of calcium 296 
this binding via the C-terminus, and also for certain residues of the NAC-region, was found to 297 
be increased. We refer to this as extended double anchor mechanism since the double 298 
anchor has been extended to the C-terminus of alpha-synuclein. Our NMR data are 299 
consistent with a study using site specific pyrene labelling of alpha-synuclein 31. In that 300 
study, it was shown that the N-terminus of alpha-synuclein binds to synthetic vesicles in the 301 
absence of calcium, while the C-terminus does not. Upon calcium addition on its own, there 302 
is a reduction in the polarity of the C-terminus, which suggests calcium binding. Moreover, 303 
upon addition of synthetic vesicles a further reduction in the polarity was observed, 304 
supporting a calcium-dependent lipid binding of the C-terminus. Summarising the above, 305 
alpha-synuclein, in the presence of calcium, may act as an extended and strengthened 306 
double anchor between synaptic vesicles, which could cause interaction in three different 307 
ways: (i) the N- and C-terminus both tether to the same vesicle, (ii) the N-terminus binds to 308 
one vesicle while the C-terminus binds to another vesicle via an extended double anchor 309 
mechanism, or (iii) the N-terminus binds to synaptic vesicles, whereas the C-terminus binds 310 
to the plasma membrane. Our observations, using synaptosomes, isolated synaptic vesicles 311 
as well as ventral mesencephalic cells, suggest that calcium and alpha-synuclein can affect 312 
vesicle pool homeostasis, either via promoting intervesicular interactions and/or via 313 
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tethering of synaptic vesicles to the plasma membrane, which could influence their 314 
proximity to voltage gated calcium channels 32.  315 
 316 
From the time of its discovery, alpha-synuclein has been known as a pre-synaptic protein, 317 
suggesting a role in neurotransmitter release. It has been shown that the overexpression of 318 
alpha-synuclein inhibits neurotransmitter release 33–37, while neurotransmitter release 319 
appears facilitated in an alpha-synuclein knock-out model 38–41. However, data are not 320 
conclusive so far and a regulatory role rather than a direct role of alpha-synuclein in 321 
exocytosis is still debated in the literature 42. It has furthermore been suggested that alpha-322 
synuclein plays a role in endocytosis and in synaptic vesicle homeostasis (for detailed review 323 
see 43).  324 
 325 
We show here, that in synaptosomes alpha-synuclein localization is dependent on calcium 326 
since calcium depletion in the extracellular space does not lead to the polarization of alpha-327 
synuclein in the synaptosomes. It is interesting to note that we see little overlap between 328 
alpha-synuclein and VAMP2 which could be interpreted as if alpha-synuclein does not bind 329 
to synaptic vesicles at all. We do, however, not believe that this is the case for two main 330 
reasons: First, all our in vitro data as well as data from others 5–10 show strong binding of 331 
alpha-synuclein to synaptic vesicles. Second, it has been suggested that alpha-synuclein 332 
binds to only a subset of synaptic vesicles 19, however, it may require further investigations 333 
to fully determine which synaptic vesicles are positive for which synaptic vesicle protein.  334 
We show that calcium as well as increased alpha-synuclein concentrations influence the 335 
clustering of synaptic vesicles in vitro. Similar observations were made using synaptic 336 
vesicle-mimics built of anionic phospholipids containing SNARE complex proteins 44. The 337 
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authors showed that an increased alpha-synuclein concentration caused clustering of the 338 
synaptic vesicle-mimics, which was dependent on the capacity of alpha-synuclein to bind to 339 
lipids, as the lipid-binding deficient familial A30P alpha-synuclein mutant displayed a 340 
decreased propensity to cluster vesicles. The authors report that also C-terminally truncated 341 
alpha-synuclein can decrease vesicle clustering, which supports our hypothesis of an 342 
extended double anchor binding mechanism of alpha-synuclein. The authors though indicate 343 
that this is mediated via C-terminal binding of alpha-synuclein to VAMP2. In our study, 344 
however, we do not observe clustering of VAMP2, suggesting that a VAMP2-independent 345 
mechanism might be involved. Our proposed model of alpha-synuclein-dependent vesicle 346 
clustering is further supported by recent studies demonstrating a decrease in synaptic 347 
vesicle motility in neurons upon alpha-synuclein overexpression 45,46. This is in line with our 348 
observation that the overexpression of wild-type human alpha-synuclein reduced the 349 
propensity of alpha-synuclein to be polarized upon calcium treatment in synaptosomes. It is 350 
important to note though that not all of these calcium-controlled processes rely solely on 351 
the presence of alpha-synuclein. This becomes clear from alpha-synuclein knock-out studies 352 
in mice 41,47 but is further supported by the fact, that alpha-synuclein is expressed at late 353 
stages of development, as shown for songbirds, for which alpha-synuclein becomes 354 
upregulated during song acquisition 48.  355 
 356 
Furthermore, we show here that dopamine toxicity known to induce alpha-synuclein 357 
oligomerization 20–23,49 can be significantly reduced if either calcium levels are decreased, 358 
using the CaV1.3 blocker isradipine, or if alpha-synuclein levels are reduced by knocking 359 
down alpha-synuclein, suggesting that both calcium and alpha-synuclein need to be present 360 
to convey dopamine-induced toxicity. This is in line with the findings that dopaminergic 361 
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neurons of the substantia nigra (SN) display a lower abundance of calcium-binding proteins 362 
50 and exhibit a calcium-driven pacemaking activity 51, putting them at higher risk for 363 
calcium-mediated pathophysiology. Using in vitro aggregation assays, we see that calcium 364 
clearly aggravates alpha-synuclein aggregation, in the presence or absence of synaptic 365 
vesicles.  We also observed an increase in nucleation when synaptic vesicles were added to 366 
alpha-synuclein with EGTA, which is in line with the literature reporting that synthetic lipids 367 
increase the rate of aggregation of alpha-synuclein 52. Excess calcium can cause a 368 
conformational change within the protein, such as by an exposure of the NAC-region upon 369 
calcium binding, or simply via a change in the net charge of the protein, both facilitating the 370 
propensity for aggregation. It is interesting to note though that alpha-synuclein fibrils 371 
formed in vitro in the presence of isolated synaptic vesicles display a different morphology.  372 
 373 
Understanding the above described role of alpha-synuclein in physiological or pathological 374 
processes may impact strongly on the development of new therapeutics for PD. 375 
Interestingly, antibodies targeted to the C-terminus of alpha-synuclein were demonstrated 376 
to decrease intracellular alpha-synuclein pathology in animal models of synucleinopathy 53. 377 
One such antibody, PRX002, is currently in phase 2 clinical development for Parkinson’s 378 
disease (ClinicalTrials.gov Identifier: NCT03100149). Also isradipine, which is used as calcium 379 
channel blocker in heart diseases, may prove to be a valuable candidate to act against PD via 380 
lowering intracellular calcium load 54,55 (ClinicalTrials.gov Identifier: NCT02168842). 381 
 382 
Methods  383 
Purification of alpha-synuclein  384 
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Human wild-type (WT) alpha-synuclein was expressed in Escherichia coli One Shot® BL21 385 
STAR™ (DE3) (Invitrogen, Thermo Fisher Scientific, Cheshire, UK) cells using plasmid pT7-7 386 
and purified using ion exchange on a HiPrep Q FF 16/10 anion exchange column (GE 387 
Healthcare, Uppsala, Sweden) 56. Alpha-synuclein was then further purified on a HiPrep 388 
Phenyl FF 16/10 (High Sub) hydrophobic interaction column (GE Healthcare) 57. Purification 389 
was performed on an ÄKTA Pure (GE Healthcare, Sweden). Monomeric protein was dialyzed 390 
against 20 mM Na2HPO4 pH 7.2 and stored at -80 °C. For experiments with dye-labelled 391 
alpha-synuclein, the cysteine mutant N122C was purified and labeled with the ATTO-647N 392 
dye (#05316, Sigma-Aldrich, Dorset, UK). For experiments with vesicles, monomeric human 393 
WT alpha-synuclein was buffer exchanged using PD10 Desalting Columns (GE Healthcare) 394 
into vesicle buffer (20 mM NaCl, 2.5 mM KCl, 25 mM HEPES, 30 mM Glucose, pH7.4 with 395 
NaOH). 396 
 397 
Lipid pull down assay  398 
Lipid extract from bovine brain (Type I, Folch Fraction I; Sigma-Aldrich) was dissolved in lipid 399 
buffer (1 mg/ml; 50 mM Tris + 100 mM NaCl, pH 7.4) and sonicated on ice using a Branson 400 
SLPe sonicator (Branson Ultrasonic S.A., Geneva, Switzerland). The lipid was incubated with 401 
2 µg of recombinant human alpha-synuclein with either KCl (50 mM), NaCl (150 or 300 mM), 402 
MgCl2 (1 mM) or CaCl2 (1 mM), for 1 h at room temperature (RT). The different samples 403 
were centrifuged for 20 min at 4000 x g at RT to obtain the pellet for analysis by Western 404 
blot. The lipid pull down assay to prove reversibility of Ca2+-dependent lipid binding was 405 
done using post-incubation with EGTA (5 mM) for one 1 hour.  406 
Western blot of alpha-synuclein was performed using 4-12% Bis-Tris gels (Life Technologies), 407 
the protein was transferred onto 0.2 µm Millipore PVDF membrane (Fisher Scientific, 408 
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Loughborough, UK) and subsequently fixed using 0.4% formaldehyde (Sigma-Aldrich) and 409 
0.1% glutaraldehyde (Sigma-Aldrich). The primary mouse anti-alpha-synuclein antibody 410 
LB509 (LB509, 1:1000 dilution, Life Technologies) and an enhanced chemoluminescence 411 
(ECL)-horse radish peroxidase (HRP) conjugated secondary antibody (NA931, 1:1000 dilution, 412 
GE Healthcare) and SuperSignal West Femto Chemiluminescent Substrate (Thermo Fisher 413 
Scientific, Epsom, UK) were used to probe the membrane, which was exposed using a G:BOX 414 
(Syngene, Cambridge, UK).  415 
 416 
Animals 417 
Animals were bred and supplied by Charles River UK Ltd., Scientific, Breeding and Supplying 418 
Establishment, registered under Animals (Scientific Procedures) Act 1986, and AAALAC 419 
International accredited. All animal work conformed to guidelines of animal husbandry as 420 
provided by the UK Home Office. Animals were sacrificed under schedule 1; procedures that 421 
do not require specific Home Office approval. Animal work was approved by the NACWO 422 
and University of Cambridge Ethics Board. 423 
 424 
Synaptic vesicles, synaptosomes and cell cultures  425 
Isolation of synaptic vesicles (SV) was performed as previously described 58. Brains were 426 
dissected from WT Sprague-Dawley rats, two brains were used per SV preparation. The 427 
vesicle pellet was resuspended in 200 µL of vesicle buffer (20 mM NaCl, 2.5 mM KCl, 25 mM 428 
HEPES, 30 mM Glucose, pH 7.4 with NaOH) and snap-frozen in aliquots in liquid nitrogen 429 
before being stored at -80°C. SVs had a protein concentration of 3.3 mg/mL.  430 
Synaptosomes were prepared from WT Sprague-Dawley adult rat brains as described 431 
previously 59. Briefly, the brain was homogenized in a glass-Teflon EUROSTAR20 432 
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homogeniser (IKA, Oxon, UK) in homogenizing buffer made from sucrose/EDTA buffer (320 433 
mM sucrose, 1 mM EDTA, 5 mM Tris, pH 7.4) with 50 mM DTT, using 10 strokes at 800 rpm. 434 
Synaptosomes were isolated using 3 % - 23 % Percoll gradients. The synaptosome containing 435 
fractions were pooled and resuspended in extracellular buffer solution (20 mM sodium 436 
HEPES, 130 mM NaCl, 5 mM NaHCO3, 1.2 mM Na2HPO4, 1mM MgCl2, 10 mM glucose, 5 mM 437 
KCl, 2.5 mM CaCl2, pH 7.4). Synaptosomes were loaded onto 8 well glass bottom µ-slides 438 
(ibidi GmbH, Munich, Germany), which were cleaned with 1 M KOH and coated with poly-L-439 
lysine 0.01 % solution (mol wt 70.000 – 150.000, Sigma-Aldrich) over night at 4°C. 440 
Synaptosomes were stimulated for 30 min at 37 °C with extracellular solution made at either 441 
5 mM KCl + 2.5 mM CaCl2, 5 mM KCl + 1 mM EGTA or 70 mM KCl + 2.5 mM CaCl2. 442 
Synaptosomes were then fixed with 4 % formaldehyde (Sigma-Aldrich) in PBS. Fixation was 443 
quenched by washing with 0.1 M glycine in PBS for 5 min. 444 
Ventral mesencephalic (VM) neurons were dissected from E14 Sprague-Dawley rat embryos. 445 
In brief, VM tissue was incubated in 0.1% trypsin (Worthington Biochemical Corporation, 446 
Lakewood, USA) and 0.05% DNase (Sigma-Aldrich) in DMEM (Sigma-Aldrich) for 20 min at 447 
37°C. Cells were washed 4 times with 0.05% DNase in DMEM and triturated until a single cell 448 
suspension was reached. Neurons were seeded at 100,000 cells/well in LabTek II chambered 449 
coverglass (Thermo Fisher Scientific) coated with poly-L-lysine 0.01 % solution (mol wt 450 
70.000 - 150.000, Sigma-Aldrich). Neurons were kept in DMEM with 10 % fetal bovine serum 451 
(FBS, 10270-106, Gibco®) for 3 hours, then media was changed to Neurobasal media Gibco® 452 
supplemented with 2 % B27 Gibco®, 0.5 mM GlutaMax Gibco® and 1 % antibiotic-453 
antimycotic Gibco® (all Thermo Fisher Scientific). Neurons were used at days in vitro (DIV) 454 
14. Fixation was performed for 10 min using 4 % formaldehyde (Sigma-Aldrich) in PBS 455 
containing 4 % sucrose, 5 mM MgCl2 and 10 mM EGTA.  456 
20 
 
Human neuroblastoma cells (SH-SY5Y) were obtained from the European Collection of Cell 457 
Cultures (ECACC, Sigma-Aldrich) and grown in a 1:1 minimal essential medium (MEM) 458 
(Sigma-Aldrich) and nutrient mixture F-12 Ham (Sigma-Aldrich) supplemented with 15 % FBS 459 
Gibco®, 1 % non-essential amino-acids Gibco®, 2 mM GlutaMAX Gibco® and 1 % antibiotic-460 
antimycotic Gibco® (all Thermo Fisher Scientific). Cells were plated at 5,000 cells/well in 461 
Nunc MicroWell 96 well plates (Thermo Fisher Scientific) for cytotoxicity assays and at 462 
700,000 cells/dish in 48 mm dishes (Nunc A/A) for western blotting studies. Cells were 463 
tested for mycoplasma contamination. 464 
Treatment of cells was performed using 100 µM dopamine (100x stock solution in water, 465 
freshly prepared, Sigma-Aldrich) or 100 µM dopamine + 5 µM isradipine (1000x stock 466 
solution in DMSO, Sigma-Aldrich). Control cells received 0.1 % DMSO and 1 % water, 467 
respectively. Isradipine treatment was carried out 30 min early to dopamine treatment. 468 
After 72 hours of incubation, cells were fixed or underwent cytotoxicity assay using the cell 469 
cytotoxicity assay kit, ab112118 (Abcam, Cambridge, UK) according to manufacturer’s 470 
instructions. Absorbance intensity was measured at 570 nm and 605 nm, with the ratio 471 
OD570/OD605 being proportional to the number of viable cells.  472 
 473 
Solution NMR 474 
In order to probe the structure and thermodynamics of calcium binding with alpha-synuclein 475 
at a residue specific level, we employed a series of 1H-15N HSQC experiments using different 476 
concentrations of Ca2+ (0.0 mM to 3.6 mM) and a fixed concentration of alpha-synuclein 477 
(200 μM). NMR experiments were carried out at 10 °C on a Bruker spectrometer operating 478 
at 1H frequencies of 800 MHz equipped with triple resonance HCN cryo-probe. The 1H-15N 479 
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HSQC experiments were recorded using a data matrix consisting of 2048 (t2, 
1H) × 220 (t1, 480 
15N) complex points. Assignments of the resonances in 1H-15N-HSQC spectra of alpha-481 
synuclein were derived from our previous studies 11.  482 
The chemical shift perturbation in the 1H-15N HSQC spectra was analysed using a weighting 483 
function: 484 
∆ߜ =  ඨ
1
2
(ߜு
ଶ + 0.15ߜே
ଶ) 
These provide the fraction of bound alpha-synuclein, ߯஻, which is calculated as: 485 
߯஻ =
∆ߜ௢௕௦
∆ߜ௦௔௧
 
Where the ∆ߜ௢௕௦ is the variation of the chemical shifts of a peak of alpha-synuclein that is 486 
observed at a given [ܥܽଶା], and ∆ߜ௦௔௧ is the maximum variation obtained at saturation with 487 
an excess of calcium. ߯஻ was calculated as a function of [ܥܽଶା] for every peak of the protein, 488 
and a global ߯஻ was used to include the chemical shift variations from all the peaks 489 
associated with the major perturbations in the presence of calcium. We then used a fitting 490 
procedure based on a binding model describing ߯஻ as a function of the total [ܥܽଶା] 
17 491 
ߙݏݕ݊௎ + ܥܽଶା௅ ⇄ ߙݏݕ݊
஻(ܥܽଶା)௅ (1) 492 
Where ߙݏݕ݊௎ and ߙݏݕ݊஻ indicate free and calcium bound alpha-synuclein, L indicates the 493 
number of Ca2+ interacting with one alpha-synuclein molecule. The equilibrium dissociation 494 
constant from this model is given by 495 
ܭ஽ =  
ൣఈ௦௬௡ೆ൧ൣ஼௔మశಽ൧
[ఈ௦௬௡ಳ(஼௔మశ)ಽ]
 (2) 496 
the overall concentration of alpha-synuclein in this equilibrium is given by 497 
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[ߙݏݕ݊] =  [ߙݏݕ݊௎] +  [ߙݏݕ݊஻(ܥܽଶା)௅] (3) 498 
and the overall concentration of Ca2+ is given by  499 
[ܥܽଶା] =  ܮ([ܥܽଶା]௅ +  [ߙݏݕ݊
஻(ܥܽଶା)௅])                                                         (4) 500 
Leading to the following fitting function 501 
߯஻ =  
[ߙݏݕ݊] + ൤
ܥܽଶା
ܮ ൨ + ܭ஽ −
ඨ൬[ߙݏݕ݊] + ൤
ܥܽଶା
ܮ ൨ + ܭ஽൰
ଶ
−
4[ߙݏݕ݊][ܥܽଶା]
ܮ
2[ߙݏݕ݊]
 
 502 
Chemical exchange saturation transfer (CEST) NMR 503 
CEST NMR is widely used to probe the interaction of amyoloidogenic proteins60,61. Here we 504 
employed CEST measurements 11,62–65 to directly probe the equilibrium between vesicle 505 
unbound and bound states of alpha-synuclein. CEST has enhanced characteristics compared 506 
to standard heteronuclear correlation spectroscopy in probing the details of the equilibrium 507 
between NMR visible (unbound alpha-synuclein) and NMR invisible (vesicle bound alpha-508 
synuclein). These include a significant sensitivity at low vesicle:protein ratios and the 509 
avoidance of other factors that may influence the transverse relaxation rates of the protein 510 
resonances. CEST experiments were carried out at 10 °C on a Bruker spectrometer operating 511 
at 1H frequencies of 800 MHz equipped with triple resonance HCN cryo-probe. The 512 
measurements were based on 1H-15N HSQC experiments by applying constant wave 513 
saturation of 400 Hz in the 15N channel. A series of large offsets was employed (-9, -7, -5, -4, 514 
-3, -1.5, 0, 1.5, 3, 4, 5, 7, 9 kHz), and additional spectrum, saturated at -100 kHz, was 515 
recorded as a reference. The saturation of the bound state is transferred to the free state via 516 
the conformational exchange of these two states, resulting in the saturation of the peak 517 
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intensities in the visible unbound state. The CEST experiments were recorded using a data 518 
matrix consisting of 2048 (t2, 
1H) × 220 (t1, 
15N) complex points.  519 
 520 
Mass spectrometry (MS) for the determination of alpha-synuclein-Ca complexes 521 
 522 
Samples of 10 μΜ wild-type alpha-synuclein in Tris buffer (20 mM, pH 7.4) were diluted in 523 
50% methanol/ 50% dH2O (v/v) to a final concentration of 2 μM. Samples containing 3.6 mM 524 
CaCl2 were also prepared as described below. Stock solution of CaCl2 was added to the 525 
alpha-synuclein sample and gently mixed with a micropipette, and then incubated for 15 min 526 
at room temperature. The sample was then diluted with 50% methanol/ 50% dH2O (v/v) to a 527 
final protein concentration of 2 μM before MS analysis. The effect of formic acid 528 
concentration on the MS signal was also investigated: for that reason, the previous samples 529 
were also prepared with formic acid to final concentrations of 0.01, 0.1 & 1% (v/v). Samples 530 
were infused into a Synapt G2-Si mass spectrometer (Waters, USA) using a syringe pump 531 
(CorSolutions, USA) at a flow rate of 3.5 μL/min. Source temperature 80 ⁰C, cone voltage 30 532 
V, desolvation temperature 250 ⁰C, trap collision energy 4.0 V, transfer collision energy 4.0 533 
V, Source pressure 7.7x10^-6 bar, Trap pressure 8.8x10^-6 bar, IMS cell pressure 2.6x10^-7 534 
bar, Transfer pressure 8.7x10^-6 bar. All data were collected in positive ion mode. 535 
 536 
Immunofluorescence  537 
Blocking and permeabilization were performed using 5 % serum and 0.01 % digitonin in 538 
phosphate buffered saline (PBS) for 1 h. Primary antibodies were incubated for 1 hour, 539 
followed by 4 washes with PBS. Secondary antibodies were incubated for 10 min, followed 540 
by 4 washes with PBS. For staining of synaptosomes no digitonin was used, instead all 541 
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solutions contained 0.05% Tween-20. Samples were kept in PBS containing 5 mM sodium 542 
azide (Sigma-Aldrich). 543 
For STED imaging of synaptic vesicles, two primary antibodies, targeting the two most 544 
abundant SV proteins 13 synaptophysin (101002, 1:750 dilution, SYnaptic SYstems, 545 
Goettingen, Germany) and VAMP2 (104202, 1:750 dilution, SYnaptic SYstems) were used in 546 
purpose of improved signal to noise ratio. A secondary anti-rabbit antibody conjugated with 547 
ATTO-647N (40839, 1:100 dilution, Sigma-Aldrich) was used to detect both primary 548 
antibodies simultaneously. For combined confocal/STED imaging of synaptic vesicles and 549 
alpha-synuclein, vesicles were stained with a primary antibody for synaptotagmin 1 (105103, 550 
1:500 dilution, SYnaptic SYstems) and a secondary anti-rabbit antibody conjugated with 551 
Alexa-488 (18772, 1:100 dilution, Sigma-Aldrich).  552 
Synaptosomes were stained for alpha-synuclein (D37A6 XP®, 1:500 dilution, rabbit, Cell 553 
Signalling, Danvers, US) and VAMP2 (104211, 1:500 dilution, mouse, SYnaptic SYstems, 554 
Goettingen, Germany). As secondary antibodies anti-rabbit Alexa Fluor®647 (ab150067, 555 
1:200 dilution, Abcam) and anti-mouse Alexa Fluor®568 (ab175700, 1:200 dilution, Abcam) 556 
were used.  557 
VM neurons were stained for alpha-synuclein (ab6162, 1:300 dilution, sheep, Abcam) and 558 
synaptotagmin 1 (105103, 1:500 dilution, rabbit, SYnaptic SYstems). As secondary antibodies 559 
anti-sheep Alexa Fluor®647 (A21448, 1:200 dilution, Life Technologies) and anti-rabbit Alexa 560 
Fluor®568 (A11036, 1:1000 dilution, Life Technologies) were used. Postfixation was 561 
performed with 4 % formaldehyde (Sigma-Aldrich) for 10 min to minimize the occurrence of 562 
detached fluorophore which would interfere with dSTORM imaging. 563 
 564 
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TEM, STED and dSTORM 565 
For transmission electron microscopy (TEM) imaging of synaptic vesicles 1 µL of SVs (3.3 566 
mg/mL) were incubated in 50 µL of vesicle buffer at 37 °C with and without 50 µM 567 
monomeric alpha-synuclein for 4 days without shaking. 10 µL of each sample was incubated 568 
on glow-discharged carbon coated copper grids for 1 min before washing twice with dH2O. 569 
2% uranyl acetate was used to negatively stain the samples for 30 s before imaging on the 570 
Tecnai G2 80-200kv TEM at the Cambridge Advanced Imaging Centre.  571 
For stimulated emission depletion (STED) imaging 0.5 µL of SVs (3.3 mg/mL) in 100 µL vesicle 572 
buffer were incubated with either 200 µM CaCl2 or 1 mM EGTA, with or without 50 µM WT 573 
unlabelled alpha-synuclein. The mixture was taken up and down a 30 G needle to disperse 574 
the SV, before incubating at 37°C for 24 hours using Lo-Bind Protein Eppendorf tubes. 8 well 575 
glass bottom µ-slides (ibidi GmbH, Munich, Germany) were coated with Biotin-PEG-576 
cholesterol according to the protocol described previously 66 and synaptic vesicles were 577 
allowed to adhere for 1 hour at RT. SVs were fixed with 4% formaldehyde (Sigma-Aldrich) in 578 
PBS for 30 minutes and washed three times with PBS, staining was performed as described 579 
above. For combined confocal/STED imaging 50 µM human WT alpha-synuclein was 580 
complemented with 10% of alpha-synuclein N122C mutant labeled with ATTO-647N dye 581 
(05316, Sigma-Aldrich). This allowed direct imaging of alpha-synuclein, while synaptic 582 
vesicles were immunolabelled as described above. STED imaging was performed on a home-583 
built pulsed STED microscope 12. STED excitation (λexc = 640 nm) and depletion (λdepl = 765 584 
nm) were generated from the same titanium sapphire oscillator operating at 765 nm. The 585 
beam was divided between two paths. In the excitation path, a supercontinuum was 586 
generated by pumping a photonic crystal fiber (SCG800, NKT photonics, Cologne, Germany) 587 
and the excitation wavelength was selected by a bandpass filter (637/7 BrightLine HC, 588 
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Semrock, NY, USA). Excitation and depletion pulse lengths were stretched to 56 ps and 100 589 
ps respectively through propagation in SF66 glass and polarization maintaining single mode 590 
fibers. The depletion beam was spatially shaped into a vortex beam by a spatial light 591 
modulator (X10468 02, Hamamatsu Photonics, Hamamatsu City, Japan) and the beams were 592 
recombined using a spatial light modulator. Imaging was performed using a commercial 593 
point scanning microscope (Abberior Instruments, Göttingen, Germany) comprising the 594 
microscope frame (IX83, Olympus, Shinjiuku, Japan), a set of galvanometer mirrors (Quad 595 
scanner, Abberior Instruments) and a detection unit. A 100X/1.4 NA oil immersion objective 596 
(UPLSAPO 100XO, Olympus) and the Inspector software was used for data acquisition 597 
(Andreas Schönle, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany). 598 
Fluorescence emission was descanned, focused onto a pinhole and detected using an 599 
avalanche photodiode (SPCM-AQRH, Excelitas Technologies. Waltham, USA). A field of view 600 
of 20 x 20 µm2 and 20 nm pixel size was used. Confocal images of ATTO488 labeled vesicles 601 
were correlated with STED images. Images were acquired on the same system as described 602 
above. Fluorescence excitation at 488 nm (Cobolt 06-MLD, Cobolt, Solna, Sweden). 603 
Fluorescence emission was filtered by a dichroic mirror (ZT594rdc, Chroma, Olching, 604 
Germany) and a bandpass filter (FF01-550/88-25, Semrock). 6 images were analysed per 605 
condition for 3 experiments. 606 
 607 
Direct stochastic optical reconstruction microscopy (dSTORM) was performed as previously 608 
described 67. Briefly, imaging was performed on a Nikon TE inverted microscope using a 609 
100x, 1.49 NA TIRF objective lens (Nikon UK Ltd.). Excitation at 640 nm (Toptica Photonic AG, 610 
Graefelfing, Germany) was used for Alexa Fluor®647 and 561 nm (Oxxius SLIM-561) for Alexa 611 
Fluor®568. Laser beams were collimated and combined by dichroic mirrors and expanded to 612 
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illuminate the sample for widefield fluorescence microscopy. A 405 nm (120 mW) 613 
(Mitsubishi Electronics Corp., Tokyo, Japan) laser was used as reactivation source. The 614 
fluorescence light in the detection path was separated from the illumination light by a 615 
dichroic filter cube (Semrock multi-edge dichroic Di01-R405/488/561/635-25x36 followed by 616 
a FF01-446/523/600/677-25 filter, Semrock, Rochester NY, USA) and was subsequently 617 
filtered further using additional band-pass filters (Semrock BP-607/35-25 or BP-642/35-25 618 
for Alexa Fluor®647 and Alexa Fluor®568 respectively). An electron-multiplying charge-619 
coupled device (EM-CCD) camera (Andor iXon DV887 ECS-BV, Andor, Belfast, Northern 620 
Ireland) was used for detection. The excitation intensity was 2 kW/cm2 for the 640 nm laser 621 
and 5 kW/cm2 for the 561 nm laser. Single-molecule photoswitching of the Alexa Fluor® 647 622 
and Alexa Fluor® 568 were performed in thiol-containing switching buffer 68 using 100 mM 623 
mercaptoethylamine (MEA) in PBS, adjusted to pH 10 using 1 M KOH. Imaging was 624 
performed in highly inclined (HiLo) illumination mode 69. 16 000 image frames with exposure 625 
times between 7.18 and 20 ms were recorded and subsequently reconstructed using either 626 
rapidSTORM 3.3 70 or the open source rainSTORM software developed in-house 71 written in 627 
MATLAB (The MathWork Inc., Natick, USA). Image overlays were assembled in FIJI 72, 628 
experiments described were repeated at least three times and all images were processed as 629 
described in the following section. 630 
 631 
Image Analysis 632 
Western blots were analysed in FIJI 72. For the analysis of synaptosomal alpha-synuclein and 633 
VAMP2 distribution, individual synaptosomes and their associated fluorophore localizations 634 
as found by rapidSTORM were segmented from the aligned overlay-images using a custom-635 
written Matlab script. From the data files, the size for alpha-synuclein distribution and 636 
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VAMP2 distribution per synaptosomes were measured using a cluster analysis algorithm 637 
with Ripley’s K function as cluster size metric 73. In short, the algorithm measures the 638 
Euclidian distances between each localization with every other one. A histogram of the 639 
distances is then generated and normalized by a histogram as expected from randomly 640 
placed localizations at the same mean density. The maximum distance value of the 641 
normalized histogram then yields a measure for the radius of the localization clusters. For 642 
image analysis of synaptic vesicles, the spot detector plugin of the image analysis software 643 
ICY was used to identify vesicles 74,75, followed by analysis using an in-house MATLAB script 644 
to calculate the number of vesicles within a 250 nm radius (see code for image analysis of 645 
synaptic vesicle STED images in Supplementary Methods). Analysis of alpha-synuclein and 646 
synaptotagmin 1 in ventral midbrain neurons was performed using the particle analysis 647 
plugin of the image analysis software FIJI 72. For colocalisation analysis, the Coloc 2 plugin 648 
was used 76, based on Pearson’s correlation analysis. 649 
 650 
ThT Assay and SEC-HPLC quantification of alpha-synuclein monomer  651 
 652 
The aggregation of alpha-synuclein was measured by Thioflavin T (ThT) assay. Briefly, 10 µM 653 
ThT was incubated with 100 µL of 100 µM alpha-synuclein with 2.5 mM CaCl2 or 1 mM EGTA 654 
with and without 1 µL 3.3 mg/mL SV. Assays were performed in non-binding, clear bottom, 655 
black 96-well plates (PN 655906 Greiner Bio-One GmbH, Essen, Germany) which were sealed 656 
with an Ampliseal transparent microplate sealer (Greiner Bio-One GmbH). Plates were 657 
incubated with orbital shaking at 300 rpm at 37 °C and the readings of ThT fluorescence 658 
intensity at 486 nm were collected every 16 min for 300 cycles in the top excitation/emission 659 
mode at a focal height of 5.5 mm. Excitation was set at 440 nm with 2 flashes using 10% of 660 
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the excitation light (Envision 2104 Multilabel Reader, PerkinElmer, Turku, Finland). 661 
Experiments were repeated three times with six replicates for each condition. The lag time 662 
was calculated by extension of a linear fit to the elongation phase, passing through the 663 
baseline using the equation: y = a + b * x. k1 (nucleation rate constant) and k2 (growth rate 664 
constant) were calculated from the Finke-Watzky two-step model fitted to sigmoidal curves 665 
of ThT fluorescence 25,77 using the equation below: 666 
[ܤ]௧ = [ܣ]଴ −
݇ଵ
݇ଶ
+ [ܣ]଴
1 +
݇ଵ
݇ଶ[ܣ]଴
exp (݇ଵ + ݇ଶ [ܣ]଴ݐ) 
 
, where [B]t is the concentration of product, [A]0 is the concentration of reactant at time 0 h, 667 
k1 is the nucleation rate constant and k2 the elongation rate constant. 668 
10 µL samples of alpha-synuclein fibrils were taken from each condition of the ThT assay and 669 
imaged by TEM as described above. Then, samples were removed from the wells and 670 
centrifuged at 21,100 x g for 1 hour at RT to pellet fibrils and oligomers. The supernatant 671 
was removed for quantitative analysis by size exclusion chromatography (SEC). SEC analysis 672 
was performed on Agilent 1260 Infinity HPLC system (Agilent Technologies LDA UK Limited, 673 
Stockport, UK) equipped with an autosampler and a diode-array detector using BioSep-SEC-674 
2000s column (Phenomenex, Macclesfield, UK) in phosphate-buffered saline (Gibco® PBS, 675 
Thermo Fischer Scientific) at 1 mL/min flow-rate. The elution profile was monitored by UV 676 
absorption at 220 and 280 nm. Remaining monomer concentration of alpha-synuclein was 677 
calculated from a calibration curve. Remaining monomer concentration for samples with SVs 678 
could not be calculated due to the presence of contaminating SV proteins obscuring the 679 
monomeric alpha-synuclein chromatographic profile. 680 
 681 
Statistics 682 
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Statistical analysis was performed using GraphPad Prism 6.07 (GraphPad Software, Inc., La 683 
Jolla, CA, USA). Values are given as mean ± sem unless otherwise stated. Either two-tailed t-684 
test or one-way ANOVA with Tukey’s post hoc correction were used as indicated. 685 
Significance was considered at p < 0.05. 686 
 687 
Data availability 688 
All relevant data are available from the authors. 689 
 690 
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Figure Legends  905 
Figure 1. Calcium binding to the C-terminus of alpha-synuclein and lipid binding  906 
(A) 1H-15N HSQC NMR spectrum of alpha-synuclein in the absence (red) and in the presence 907 
of calcium (green, 1.6 mM calcium). Major chemical shift perturbations in the presence of 908 
calcium are located at the C-terminus of alpha-synuclein (red arrows with assigned amino 909 
acid residues), while peak broadening (blue arrows with assigned amino acid residues) can 910 
be seen within the NAC-region.  911 
(B) Fitting of alpha-synuclein calcium binding (KD) from 1H-15N HSQC NMR spectra at 912 
increasing calcium concentrations, where L indicates the number of Ca2+ ions interacting 913 
with one alpha-synuclein molecule. 914 
(C) Calcium-bound alpha-synuclein species directly observed by mass spectrometry. 915 
Electrospray ionisation mass spectra were acquired under identical instrument conditions 916 
for samples incubated with or without calcium. Multiple alpha-synuclein species were 917 
observed upon charge deconvolution of the ion envelope for the 9+ - 19+ charge states, 918 
inclusive. The masses correspond to alpha-synuclein: calcium complexes up to a 919 
stoichiometry of 1:6. 920 
(D) Lipid pull down experiment using lipids from Folch brain extracts, recombinant alpha-921 
synuclein and various ions. Western blot of the amount of protein pulled down shows that 922 
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more alpha-synuclein was pulled down by the lipids in the presence of calcium. Neither 923 
potassium, sodium, nor magnesium increased alpha-synuclein lipid binding to the same 924 
extent. **p = 0.0011, 0.0022 and 0.0090 for comparison of 1 mM CaCl2 with a-syn control, 925 
50 mM KCl, and 150 mM NaCl, respectively. Calculated using one-way ANOVA with Tukey’s 926 
post hoc correction, graphs indicate mean +/- s.e.m.. N = 3 for all groups, corresponding to 3 927 
biological repeats, d.f. 12. 928 
 929 
Figure 2. The C-terminus of alpha-synuclein binds to synaptic vesicles upon calcium binding  930 
(A) CEST NMR experiments were performed on alpha-synuclein and synaptic vesicles in the 931 
absence (black) or presence of calcium (red, 6 mM). In the absence of calcium, the N-932 
terminus shows the strongest interaction with synaptic vesicles. Upon addition of calcium, 933 
the interaction of the C-terminus and also of some residues of the NAC-region increases, 934 
which is seen as a reduction of the signal. Experiments were repeated twice. 935 
(B) Lipid pull down experiment showing the transient nature of alpha-synuclein lipid binding. 936 
Western blot of the amount of alpha-synuclein pulled down by the lipids showing that 937 
calcium-induced lipid binding of alpha-synuclein is reversible upon addition of the calcium 938 
chelator EGTA. *p = 0.0263, calculated using one-way ANOVA with Tukey’s post hoc 939 
correction, graphs indicate mean +/- s.e.m.. N = 6 for control and CaCl2, n = 4 for EGTA and 940 
CaCl2 + EGTA, data from 3 biological repeats, d.f. 16. 941 
(C) dSTORM super-resolution imaging of alpha-synuclein and VAMP2 on isolated 942 
synaptosomes displaying alpha-synuclein clustering under normal physiological conditions 943 
with 2.5 mM calcium in the extracellular buffer (upper panel). Upon calcium depletion in the 944 
extracellular buffer, using 1 mM EGTA, alpha-synuclein localization was dispersed (lower 945 
panel). 946 
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(D) Cluster analysis of alpha-synuclein and VAMP2 immunostaining showing increased 947 
cluster size of alpha-synuclein upon calcium depletion, while VAMP2 cluster size is the same 948 
either in the presence of calcium or upon calcium depletion in the extracellular buffer. 949 
****p < 0.0001, nsp = 0.6363 calculated using two-tailed t-test, graphs indicate mean +/- 950 
s.e.m.. N = 22 for + Ca2+ and n = 30 for - Ca2+, where n indicates single synaptosomes, data 951 
form 3 biological repeats, d.f. 50. 952 
 953 
Figure 3. Alpha-synuclein and calcium balance the interaction of synaptic vesicles  954 
(A) STED super-resolution imaging of isolated synaptic vesicles incubated with 1 mM EGTA, 955 
200 µM calcium, 50 µM alpha-synuclein + 200 µM calcium, or 50 µM alpha-synuclein + 1 mM 956 
EGTA. Images show synaptic vesicles circled in red as detected for analysis of synaptic vesicle 957 
clustering. Scales represent 200 nm. Synaptic vesicle clustering is shown as a decrease of 958 
synaptic vesicles found as single vesicles and as an increase of synaptic vesicles found in 959 
clusters was seen upon incubation of synaptic vesicles with either increased calcium or 960 
alpha-synuclein. Note, EGTA was not able to reduce synaptic vesicle clustering in the 961 
presence of increased alpha-synuclein concentrations. **p = 0.0023, ****p < 0.0001 and **p 962 
= 0.0012 for comparison of % of single vesicles, *p = 0.0140, ***p = 0.0001 and *p = 0.0136 963 
for comparison of % of vesicle clusters of two. Calculated using two-way ANOVA with 964 
Tukey’s post hoc correction, graphs indicate mean +/- s.e.m.. N = 18 for all conditions, data 965 
from biological 3 repeats, d.f. 272. 966 
(B) TEM images of synaptic vesicles showing synaptic vesicle clustering in the presence of 50 967 
µM alpha-synuclein.  968 
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(C) Combined imaging of synaptic vesicles (confocal) and ATTO647N labelled alpha-synuclein 969 
(STED) showing synaptic vesicles surrounded and glued together by alpha-synuclein. 2 970 
biological repeats. 971 
 972 
Figure 4. Calcium and alpha-synuclein levels mediate dopamine toxicity 973 
(A-C) Ventral midbrain neurons were incubated with 100 µM dopamine in the presence or 974 
absence of 5 µM isradipine. dSTORM super-resolution microscopy of alpha-synuclein and 975 
synaptotagmin 1 after 72 h revealed an increase in the area of alpha-synuclein puncta, an 976 
increase in the size of synaptotagmin 1 puncta and an increased colocalization of alpha-977 
synuclein with synaptotagmin 1 upon dopamine treatment. These effects were reversed by 978 
the Cav1.3 calcium channel antagonist isradipine, showing decreased size of alpha-synuclein 979 
and synaptotagmin-1 puncta and decreased colocalization. ****p < 0.0001 for 980 
synaptotagmin and alpha-synuclein, **p < 0.0066, *p < 0.0446 for colocalization, calculated 981 
using one-way ANOVA with Tukey’s post hoc correction, graphs indicate mean +/- s.e.m.. N = 982 
2251, 1154, 1987 for synaptotagmin, d.f. 5353, n = 5198, 3210, 6845 for alpha-synuclein, d.f. 983 
15250, where n indicates individual clusters identified from 30, 30, 29 images from 3 984 
biological repeats, n= 30, 30, 29 for colocalization, where n indicates number of images.  985 
(D) Dopamine toxicity in SH-SY5Y cells after 72 h incubation with 100 µM dopamine was 986 
rescued upon treatment with 5 µM isradipine and upon alpha-synuclein knock-down, 987 
showing that both, calcium and alpha-synuclein are necessary for toxicity to occur. ***p < 988 
0.0007, nsp = 0.9935 for isradipine, n = 12 for all groups, where n indicates number of wells, 989 
d.f. 44; **p < 0.0062, nsp = 0.9934 for alpha-synuclein knock-out, n = 8 for all groups, where 990 
n indicates wells, d.f. 28, calculated using one-way ANOVA with Tukey’s post hoc correction, 991 
graphs indicate mean +/- s.e.m.. 3 biological repeats. 992 
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 993 
Figure 5. The effect of calcium and synaptic vesicles on alpha-synuclein aggregation  994 
(A) Alpha-synuclein aggregation measured by ThT fluorescence using 100 µM monomeric 995 
alpha-synuclein under shaking conditions. The presence of 2.5 mM calcium increased the 996 
aggregation kinetics of alpha-synuclein compared to 1 mM EGTA, both in the presence or 997 
absence of synaptic vesicles (black and red). For the EGTA-containing groups there was a 998 
trend towards faster aggregation of alpha synuclein in the presence of synaptic vesicles (blue 999 
vs. grey). 3 biological repeats, n = 18 for all conditions, where n represents single wells. 1000 
values represent mean +/- s.e.m..  1001 
 (B) TEM images of alpha-synuclein fibrils formed in the presence of 2.5 mM calcium or 1 1002 
mM EGTA either in the presence or absence of synaptic vesicles. Differences in the 1003 
morphology of alpha-synuclein fibrils were observed for fibrils formed in the presence of 2.5 1004 
mM calcium in the absence and presence of synaptic vesicles. In the presence of synaptic 1005 
vesicles alpha-synuclein fibrils showed increased lateral bundling and shortening. Alpha-1006 
synuclein aggregation in the presence of 1 mM EGTA led to substantially less fibrils, however 1007 
the fibrils formed, retained their morphological phenotype compared to the fibrils formed in 1008 
the presence of 2.5 mM calcium. Alpha-synuclein fibrils formed in the presence of synaptic 1009 
vesicles plus 1 mM EGTA showed an intermediate phenotype, with bundled, but more 1010 
elongated fibril structures than found in the synaptic vesicles and 2.5 mM calcium group. 1011 
Experiments were repeated twice. 1012 
 1013 
Table 1. The effect of calcium and synaptic vesicles on alpha-synuclein aggregation  1014 
 1015 
Condition lag time (hours) k1 (ms
-1) k2 (s-1 %int-1) remaining monomer (µM)
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Ca2+ only  3.95 ±  0.53 0.24 ±  0.69 8.07 ± 1.28 8.5 ± 0.3 **** 
Ca2+ + SV 5.55 ± 2.59 0.78 ± 5.33 15.92 ±  5.02 _a 
EGTA only  78.95 ± 0.42 0.09 ± 0.04 6.32 ±  0.65 67.8 ± 5.4 
EGTA + SV 44.72 ± 0.42 0.22 ±  0.06 5.50 ±  0.51 _a 
 1016 
ThT fluorescence intensity profiles were used to calculate the lag time as well as the 1017 
nucleation (k1) and the elongation rate (k2). Lag time is given as X intercept with standard 1018 
error. k1 and k2 are given as constants with a 95 % confidence interval. 3 biological repeats. 1019 
Remaining alpha-synuclein monomer concentration was revealed by analytical SEC-HPLC at 1020 
the end of the experiment. ****p < 0.0001, n = 10 for Ca2+ only and n = 9 for EGTA only, 1021 
where n indicates wells, 2 biological repeats, calculated using two-tailed t-test, values 1022 
indicate mean +/- s.e.m.. d.f. 17. a Remaining monomer concentration could not be 1023 
calculated due to presence of protein from synaptic vesicles preventing clear detection of 1024 
remaining asyn monomer. 1025 
 1026 
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